ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
ASH Update on Moderate-Intensity Chemo for AML: What Are the Remission Rates & OS of AZA/VEN, and LDAC/VEN? Does OS Improve With VEN + Decitabine for TP53 Mutation in AML, and What Are the New Potential Agents?
Comments 0
Login to view comments.
Click here to Login
